BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Core Insights - Biogen's shares have increased for five consecutive days, resulting in a total return of 14% during this period, with a market value increase of approximately $3.3 billion, bringing its market capitalization to around $23 billion [3][4] - The stock is currently 1.5% higher than its closing value at the end of 2024, while the year-to-date return for the S&P 500 is at 14.2% [3] - The surge in Biogen's stock price is attributed to the regulatory approval of its Alzheimer's treatment, Leqembi, in China, with Biogen recognizing a 50% share of the drug's profits and losses [3][4] Financial Performance - Biogen's revenue from Leqembi reached $160 million in the latest quarter, with expectations for significant increases in the coming quarters due to the approval in China [4] - The company develops treatments for various neurological and neurodegenerative disorders, including multiple sclerosis and non-Hodgkin lymphoma [5] Market Context - A comparison of Biogen's stock performance against the S&P 500 indicates a positive momentum, which may reflect increasing investor confidence [7] - Currently, 80 S&P constituents have experienced three or more days of consecutive gains, while 55 have seen three or more days of consecutive losses, highlighting the broader market trends [8]